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ttp://dx.doi.org/10.1016/j.ajpath.2014.05.019Epithelial permeability is often increased in inﬂammatory bowel diseases. We hypothesized that perturbed
mitochondrial function would cause barrier dysfunction and hence epithelial mitochondria could be targeted
to treat intestinal inﬂammation. Mitochondrial dysfunction was induced in human colon-derived epithelial
cell lines or colonic biopsy specimensusing dinitrophenol, andbarrier functionwas assessed by transepithelial
ﬂux of Escherichia coli with or without mitochondria-targeted antioxidant (MTA) cotreatment. The impact of
mitochondria-targeted antioxidants on gut permeability and dextran sodium sulfate (DSS)einduced colitis in
mice was tested. Mitochondrial superoxide evoked by dinitrophenol elicited signiﬁcant internalization and
translocation of E. coli across epithelia and control colonic biopsy specimens, which was more striking in
Crohn’s diseasebiopsy specimens; themitochondria-targeted antioxidant, MitoTEMPO, inhibited thesebarrier
defects. Increased gut permeability and reduced epithelial mitochondrial voltage-dependent anion channel
expression were observed 3 days after DSS. These changes and the severity of DSS-colitis were reduced by
MitoTEMPO treatment. In vitro DSS-stimulated IL-8 production by epithelia was reduced by MitoTEMPO.
Metabolic stress evokes signiﬁcant penetration of commensal bacteria across the epithelium, which is
mediated by mitochondria-derived superoxide acting as a signaling, not a cytotoxic, molecule. MitoTEMPO
inhibited this barrier dysfunction and suppressed colitis in DSS-colitis, likely via enhancing barrier function
and inhibiting proinﬂammatory cytokine production. These novel ﬁndings support consideration of MTAs in
the maintenance of epithelial barrier function and the management of inﬂammatory bowel diseases.
(Am J Pathol 2014, 184: 2516e2527; http://dx.doi.org/10.1016/j.ajpath.2014.05.019)Supported by a Canadian Institutes of Health Research grant MPO
126005 (D.M.M.) and a Swedish Medical Research Council grant (J.D.S.).
D.M.M. holds a Tier 1 Canada Research Chair in Intestinal Immuno-
physiology.
Disclosures: M.P.M. is the inventor of MitoQ and has shares in a com-
pany commercializing MitoQ and related compounds. M.P.M. provided the
MitoQ used in this study.The mammalian gut harbors an immense and diverse micro-
biota, and host-bacteria interactions are key determinants of
digestive health and general well-being.1,2 While providing
distinct beneﬁts to the host (eg, vitamin synthesis), commensal
bacteria that cross the epithelium and enter the mucosa have
the potential to provoke inﬂammation, and movement into the
circulation can result in sepsis and death. Consequently, the
barrier function of the epithelium, both intrinsic (eg, epithelial
tight junctions and cell membranes) and extrinsic (eg, mucus)
elements, is a critical component of innate defense. Thus,
the commensal bacteria-host interaction pivots on the gut
epithelium as a point of ﬁrst contact and knowledge of thestigative Pathology.
.dynamic nature of this interface is important to understanding
normal intestinal function and disease.3
The epithelial barrier is not static; rather, it is highly dynamic
and tightly regulated to maintain gut homeostasis. However,
uncontrolled or prolonged increases in gut permeability have
Mitochondria and Epithelial Permeabilitythe potential to initiate or exaggerate enteric inﬂammatory
disease. For example, the consensus on the etiology of in-
ﬂammatory bowel disease (IBD; Crohn’s disease or ulcerative
colitis) is that disease develops because of an inappropriate
immune response to the gut microbiota in a genetically sus-
ceptible individual.4 This suggests a barrier defect because
microbes, or their products, in the gut lumen must access the
mucosal immune system by crossing the epithelial cell layer.
Although increased epithelial permeability as a primary cause
of IBD remains unproved,3 the leaky gut hypothesis5 is sup-
ported by observations in experimental models of colitis3,6,7
and increased epithelial permeability has been repeatedly
demonstrated in active IBD.8,9 Therefore, the ability to
enhance the barrier property of the epithelium would be of
value in ameliorating enteric inﬂammatory disease.
Given that control of epithelial permeability (apical junction
complex formation and transcellular permeation) is energy
dependent, mitochondria should be essential for appropriate
regulation of barrier function. Indeed, factors such as infection,
nonsteroidal anti-inﬂammatory drugs, and smoking, which can
contribute to the pathophysiological characteristics of Crohn’s
disease, also perturb mitochondrial function.10e12 Further-
more, structurally abnormal mitochondria have been observed
in tissue from patients with gut inﬂammation,13 in animal
models of gut disease,14 and in epithelial monolayers treated
with bacterial toxins or low-grade pathogens.15 However,
despite these ﬁndings and the keen interest in mitochondria in
the pathophysiological characteristics of neuromuscular dis-
ease, diabetes, and obesity,16e18 there are limited data on the
role of mitochondria in colitis.
We have previously shown that model epithelia treated with
dinitrophenol (DNP) to uncouple oxidative phosphorylation
display decreased barrier function, as characterized by lower
transepithelial resistance (TER) indicative of increased para-
cellular permeability, and the internalization and translocation
of noninvasive, nontoxigenic commensal E. coli.13,19 The
latter is particularly intriguing for two reasons: entry of
commensal bacteria into the enterocyte likely represents a
threat and the enterocytes’ response (eg, IL-8 synthesis) could
promote inﬂammation; and the contribution of transcellular
permeability to a barrier defect is not well understood and
needs to be comprehensively assessed and fully integrated to
any consideration of the epithelial barrier and innate defense.
Thus, the current study was designed to uncover the mecha-
nism(s) underlying the increased internalization and trans-
location of commensal Escherichia coli across gut epithelia,
which occurs as a consequence of metabolic stress evoked by
targeted perturbation of mitochondrial function.
Materials and Methods
Human Tissue
Human tissue was obtained and used with patient consent
following the guidelines on use of human tissue at the Univer-
sity of Calgary (Calgary, AB, Canada) and the Regional EthicsThe American Journal of Pathology - ajp.amjpathol.orgCommittee, Linköping. Animal studies were conducted at the
University of Calgary and conformed to national guidelines, as
overseen by the Health Sciences Animal Care Committee.
Reagents
DNP, rotenone, oligomycin A,20 hydrogen peroxide, N-ace-
tylcysteine, and ﬂuorescein isothiocyanate (FITC)e4-kDa
dextran were from Sigma Chemical Company (St. Louis,
MO). MitoQ (mQ) was generated by Dr. Michael Murphy
(Cambridge, UK). Killed FITCeE. coli (K12), MitoSox,
Mitotracker, and DAPI were from Molecular Probes (Eugene,
OR). Dextran sodium sulfate (DSS) was fromMPBiomedicals,
LLC (Solon, OH).MitoTEMPO (MitoT ormT)was fromSanta
Cruz Biotechnology, Inc. (Santa Cruz, CA).13,19e25 The E. coli
strains HB101 and F18 were provided by Dr. Philip M. Sher-
man (Hospital for Sick Children, University of Toronto, Tor-
onto, ON, Canada).
Cell Culture and Bacterial Translocation
The T84 and HT-29 human colonic epithelial cell lines were
maintained as described.13 A total of 106 cells/mL were seeded
into 12-well plates and used at approximately 70% conﬂuence
on the basis of phase-contrast microscopy or onto 3.0-mm
porous ﬁlter supports and cultured for 7 days until electrically
conﬂuent (T84>1000 U$cm2; HT-29>300 U$cm2).13 E. coli
(strainsHB101andF18)were grownovernight inLuria-Bertani
broth, and 106 colony-forming units (CFU) were added to the
epithelium (luminal aspect of ﬁlter-grown polarized prepara-
tions). Bacterial internalization was assessed by killing extra-
cellular bacteria with 200 mg/mL gentamicin (1 to 2 hours;
conﬁrmed by a lack of colony growth on LB plates), followed
by enterocyte lysis (0.1% Triton X-100, Sigma Chemical
Company), and culturing serial dilutions of the cell extract. In
other experiments, gentamicin was followed by extensive
washing, fresh medium was added, samples were collected 6
and 16 hours later and cultured for 24 hours on LB agar, and
CFUs were counted. Bacterial translocation was assessed by
sampling the medium from the basolateral compartment of
ﬁlter-grownepithelia.21All drugswereadded30minutesbefore
or simultaneously with the E. coli, with or without metabolic
stressor, and were tested (at the doses used) for bacteriostatic
and bacteriocidal effects.
ROS Detection and Quantiﬁcation
A total of 2 105 T84 cells were seeded onto glass coverslips,
and mitochondria-produced superoxide was detected using 5
mmol/L Mitosox Red (Molecular Probes) and mitochondria
were detected with 200 nmol/LMitotracker-Green (Molecular
Probes).22 Random images on the basis of 2 mg/mL DAPI (to
identify nuclei) staining were captured on an Olympus BX41
microscope (Olympus Canada, Markham, ON, Canada) (60
objective) with Qcapture software (Olympus Canada).22
Identical conditions and exposure times were used in each2517
Figure 1 Schematic of the experimental protocols used to assess the
impact of systemic MitoTEMPO on DSS-induced colitis in BALB/c mice.
MitoTEMPO was used in a prophylactic regimen in which mice underwent
necropsy 3 (I) or 5 (II) days after DSS or after 5 days of DSS and then 3 days
of normal water (III). When used in a treatment regimen, MitoTEMPO was
delivered after removal of the DSS water and animals underwent necropsy
on day 8 (IV).
Figure 2 Perturbed epithelial mitochondrial activity reduces barrier
function. Conﬂuent ﬁlter-grown T84 epithelial cell monolayers display
reduced TER 24 hours after exposure to E. coli (Ec; strain HB101, 106 CFU
inoculum) that is enhanced by 0.1 mmol/L DNP, 1 mmol/L rotenone (Rot), or
1 mmol/L oligomycin A (OmA) cotreatment (n Z 3 experiments, nine
epithelial preparations) (A, top panel). Epithelial ATP levels 16 hours after
treatment (n Z 9 to 12 monolayers from two experiments) (A, bottom
panel). E. coli translocation (B) and internalization (C) across ﬁlter-grown
T84 cell monolayers are signiﬁcantly increased by DNP, Rot, or OmA
cotreatment, as is E. coli internalization into plastic-grown T84 epithelia
(nZ 3 to 4 experiments, 8 to 13 epithelial preparations) (D). E: After killing
extracellular bacteria, signiﬁcant numbers of E. coli are recovered in the
culture medium from DNP-treated epithelial monolayers, which is reduced by
treatment with the mitochondria-targeted antioxidants, 10 mmol/L MitoQ
(mQ) or 10 mmol/L MitoTEMPO (mT) (nZ 4 epithelial monolayers from one
representative experiment of four experiments). F: Application of 0.5 mmol/
L H2O2 directly to plastic-grown T84 cell monolayers does not evoke
increased internalization of E. coli (n Z 3 experiments, 9 monolayers/
condition). Data are given as means  SEM. *P < 0.05 versus Ec, yP < 0.05
versus control (con), and zP < 0.05 versus Ec þ DNP.
Wang et alexperiment and set to avoid overexposure of the Mitosox,
Mitotracker Green, and DAPI ﬂuorescence.
Fluorometric Assessment of Phagosomal pH
Carboxyﬂuorescein succinimidyl esterelabeled, IgG-coupled,
3-mm silica particles were prepared for assessment of phag-
osomal pH in live murine bone marrowederived macro-
phages.26 Measurements were performed using a FLUOstar
Optima ﬂuorescent plate reader (BMG Labtech, Ortenberg,
Germany) in assay buffer consisting of PBS supplemented
with 1 mmol/L CaCl2, 2.7 mmol/L KCl, 0.5 mmol/LMgCl2, 5
mmol/L dextrose, and 0.25% gelatin. Cells were pretreated
with rotenone, oligomycin A, or DNP for 30 minutes before
addition of the particles. Phagosomal pH was calculated by
recording the ratio of the ﬂuorescent emission at 520 nm of
carboxyﬂuorescein succinimidyl ester conjugated to experi-
mental particles excited at 490 and 450 nm, followed by
polynomial regression to a standard curve using an adapted
nigericin/high Kþ method.27
Ussing Chamber Studies
Human colonic biopsy specimens, surgical specimens (exposed
surface area of 1.8 and 9.2 mm2, respectively),24 or 0.6-cm2
segments of murine midcolon28 were mounted in Ussing
chambers, and the spontaneous potential difference was clam-
ped at 0V by the automated and continuous injection of current,
the short-circuit current (ISC). After a 20-minute (murine) or
40-minute (human) equilibration, baseline ISC and potential
differencewere used to calculateTER. 51Cr-EDTA(34mCi/mL;
Perkin Elmer, Boston, MA) or dead FITC-labeled E. coli K12
(108 particles; Molecular Probes) and 0.1 mmol/L DNP were
then added to the mucosal side of the tissues, with or without
a 20-minute pretreatment with 10 mmol/L MitoTEMPO; sam-
ples were collected over a 2-hour period for ﬂux calculations.24
At the end of the experiment, a ﬁnal TER recording was made
and 105 mol/L cAMP-dependent Cl secretagogue, forskolin,
was added to the serosal side of the tissue andDISCwas recorded
as a measure of tissue viability.28,292518qPCR Analysis
Expression of ATP synthase, peroxiredoxin 1, and NADH
CoQ reductase mRNAs in colonic biopsy specimens was
assessed by real-time PCR. Total RNAwas extracted using the
PureLink RNA Mini Kit (Invitrogen, Burlington, ON, Can-
ada), cDNA was reverse transcribed from 0.5 mg of RNA with
the iScript cDNA Synthesis kit (Bio-Rad, Mississauga, ON,
Canada), and real-time PCRs were performed using reagent
concentrations and a standard protocol for iQTMSYBRGreenajp.amjpathol.org - The American Journal of Pathology
Mitochondria and Epithelial PermeabilitySupermix (Biorad, Toronto, ON, Canada). Brieﬂy, cDNAwas
incubated in a 20-mL reaction, containing 1 mL cDNA, 300
mmol/L of nucleotide primers, and 10 mL of 2 iQTM SYBR
Green Supermix (Biorad). The PCR conditions were an initial
activation step at 95C for 2 minutes, followed by a 15-second
denaturing step at 95C, an annealing step at 55C for 15 sec-
onds, and an extension step at 68Cfor 20 seconds. Forty cycles
were completed and followed by a melting curve analysis.
Expression is presented relative to the housekeeping gene, 18s
rRNA. Primers were designed using the primer3 program
(http://bioinfo.ut.ee/primer3-0.4.0/primer3, last accessed
October20, 2010) and are available athttp://www.ncbi.nlm.nih.
gov/genbank: i) ATP synthase (GenBank accession number
NM_001686.3), forward primer, 50-GCAGATTTTGGCA-
GGTGAAT-30, and reverse primer, 50-AGGGGCAAGG-
AGAGAGACA-30; ii) peroxiredoxin 1 (GenBank accessionFigure 3 Targeting mitochondria-derived superoxide reduces bacterial trans
showing mitochondria (Mitotracker) and that mitochondria-derived superoxide (M
(0.1 mmol/L); and this response is greatest after treatment with DNP and E. coli (
partially corrected by cotreatment with the mitochondria-targeted antioxidant
range Z 984 to 1974 U cm2). MitoTEMPO completely blocks the increased ba
monolayers (n Z 12 epithelia from four experiments) (C) and internalization i
experiments) (D). Barrier studies were conducted at 16 hours after treatment; effe
B. Data are given as means  SEM. *P < 0.05 versus Ec, yP < 0.05 versus contr
The American Journal of Pathology - ajp.amjpathol.orgnumber NM_006793), forward primer, 50-TGGGGTCTT-
AAAGGCTGATG-30, and reverse primer, 50-TCCCCATG-
TTTGTCAGTGAA-30; iii) NADH CoQ reductase (GenBank
accession number NM_002496.3), forward primer, 50-CCA-
CCATCAACTACCCGTTC-30, and reverse primer, 50-AAG-
CCGCAGTAGATGCACTT-30; and iv) 18s rRNA (GenBank
accession number NR_003286.2), forward primer, 50-ATAC-
ATGCCGAAGGGCGCTG-30, and reverse primer, 50-AGG-
GGCTGACCGGGTTGGTT-30.30
Colitis
Colitis was induced in 7- to 9-week-old male Balb/C mice
(Charles River Laboratories, Senneville, QC, Canada) by
administering 5% (w/v) DSS (approximately 40,000 kDa) in
their drinking water for 5 days. Animals underwent necropsycytosis across model epithelia. A: Representative epiﬂuorescence images
itoSox) is a rapid (30 minutes) and sustained (16 hours) response to DNP
Ec; inoculum at 106 CFU). B: The decrease in TER elicited by DNP þ E. coli is
s, 10 mmol/L MitoQ (mQ), or 10 mmol/L MitoTEMPO (mT) (starting TER
cterial internalization and translocation of E. coli across ﬁlter-grown T84
nto plastic-grown epithelia induced by DNP (n Z 9 epithelia from three
ct of 5 mmol/L N-acetylcysteine (NAC) as a general antioxidant is shown in
ol (con), and zP < 0.05 versus DNP þ Ec.
2519
Wang et alafter 3 or 5 days of DSS, or after 5 days of DSS and then 3 days
of normal drinkingwater, with orwithout 100 mgMitoTEMPO
(i.p.) on days 0 to 4 (prophylactic regimens). Alternatively,
mice received 5% DSS for 5 days, followed by 3 days of
normal drinking water and a once-daily treatment of Mito-
Tempo (days 5 to 7), and underwent necropsy on day 8
(Figure 1). Colitis was assessed by a disease activity score on
the basis of body weight, colon length, and macroscopic
appearance of the animal, its colon, and stool.31 Hematoxylin
and eosin (H&E)estained parafﬁn sections of mid-distal colon
were scored for histopathological features using a validated
scoring system in a blinded manner (D.M.M., A.W.).31 In
some experiments, epithelial barrier function was assessed by
either gavagingmicewith 100 mL of 50mg of FITC-dextran (3Table 1 Characteristics of Patients from Whom Colonic Resected Tissu
Analysis or qPCR
Patient no. Diagnosis Procedure
1 Colon cancer Surgery
2 Colon cancer Surgery
3 Polyp control Endoscopy
4 Polyp control Endoscopy
5 Polyp control Surgery
6 Colon cancer Surgery
7 Colon cancer Surgery
8 Colon cancer Surgery
9 Colon cancer Surgery
10 Colon cancer Surgery
11 Colon cancer Surgery
12 Colon cancer Surgery
13 Crohn’s disease Surgery
14 Crohn’s disease Surgery
15 Crohn’s disease Endoscopy
16 Crohn’s disease Endoscopy
17 Crohn’s disease Surgery
18 Crohn’s disease Surgery
19 Colon cancer screening Biopsy
20 Colon cancer screening Biopsy
21 Colon cancer screening Biopsy
22 Colon cancer screening Biopsy
23 Colon cancer screening Biopsy
24 Colon cancer screening Biopsy
25 Crohn’s disease, inactive Biopsy
26 Crohn’s disease, inactive Biopsy
27 Crohn’s disease, inactive Biopsy
28 Crohn’s disease, inactive Biopsy
29 Crohn’s disease, inactive Biopsy
30 Crohn’s disease, inactive Biopsy
31 Crohn’s disease, inactive Biopsy
32 Crohn’s disease Biopsy
33 Crohn’s disease Biopsy
34 Crohn’s disease Biopsy
34 Crohn’s disease Biopsy
36 Crohn’s disease Biopsy
37 Crohn’s disease Biopsy
For patients 1 to 18, Ussing chamber analysis was used (University of Linköping,
Calgary, Calgary, AB, Canada).
d, No data.
2520to 5 kDa;Molecular Probes) andmeasuring ﬂuorescence in the
serum 4 hours later; or excising small pieces of colon,
weighing, rinsing in gentamicin, and then serially diluting
homogenates, plating onto blood agar, culturing at 37C for 24
hours, and counting bacterial colonies.
Cytokine and ATP Production
A total of 2.5  105 T84 epithelial cells were seeded into 12-
well plates and treated with 1% to 4% DSS or 10 ng/mL
lipopolysaccharide, culture medium was collected 4 to 48
hours later, and IL-8 was measured by ELISA (R&D Systems
Inc.; assay detection limit, 9 pg/mL). ATP levels in epithelia 16
hours after exposure to DNP, rotenone, or oligomycin A werees or Biopsy Specimens Were Obtained for Use in Ussing Chamber
Sex Age (years)
Anti-inﬂammatory
medications
M 96 d
M 75 d
M 52 d
F 40 d
M 32 d
F 62 d
F 52 d
F 79 d
M 64 d
M 82 d
F 66 d
F 83 d
M 22 d
F 37 Prednisone
F 49 d
M 50 d
F 36 d
M 36 d
M 36 d
M 52 d
M 32 d
F 42 d
F 44 d
F 45 d
M 48 Prednisone, azathioprine
M 55 Methotrexate
M 57 Infliximab
F 19 Azathioprine, infliximab
M 34 Prednisone, methotrexate
M 24 Azathioprine, infliximab
M 76 Adalimumab
F 32 Azathioprine, adalimumab
M 30 Azathioprine
M 48 Salafalk
M 32 Azathioprine, adalimumab
M 42 Methotrexate
F 36 Adalimumab
Linköping, Sweden); and for patients 19 to 37, qPCR was used (University of
ajp.amjpathol.org - The American Journal of Pathology
Mitochondria and Epithelial Permeabilitymeasured by commercial assay, following the manufacturer’s
instructions (Cell Viability Assay, catalogue number G7573;
Promega, Madison, WI) and normalized to 100 mg protein.
Protein Immunodetection
Standard immunocytochemistry and immunoblotting pro-
tocols were used to detect nuclear factor, erythoid 2erelated
factor (Nrf2), a sensor of oxidative stress, in glass coverslip
or plastic-grown T84 epithelium, respectively, treated with E.
coli, DNP, or both agents.32 For immunostaining, cells were
ﬁxed for 10 minutes with 100% methanol and the primary
anti-Nrf2 antibody (sc-722; Santa Cruz Biotechnology, Inc.),
used at 1:100 dilution. For immunoblotting, the anti-Nrf2
antibody was used at 1:1000 dilution. Whole epithelial cell
extracts were assessed for expression of the mitochondrial-
speciﬁc voltage-dependent anion channel (VDAC; 1:1000,
number 4866; Cell Signaling Technology, Beverly, MA).
Statistical Analysis
Data are given as means  SEM. Multiple group compar-
isons were done by one-way analysis of variance, followed
by pairwise post hoc statistical tests, with P < 0.05 as a
level of statistical signiﬁcant difference.
Results
Perturbed Mitochondrial Function Increases Epithelial
Permeability
Disruption of T84 epithelial cell mitochondria by DNP (Hþ
ionophore), oligomycinA (inhibits ATP synthase), or rotenone
(blocks electron transport chain complex I) at the doses used
had marginal effects on TER (a measure of passive ion ﬂux)
over a 16-hour time frame; however, in the presence of
noninvasive, nonpathogenic E. coli (HB101), a signiﬁcantFigure 4 Metabolic stresseinduced decreases in epithelial barrier function in hu
human colon mounted in Ussing chambers and treated with 0.1 mmol/L DNP display
signiﬁcantly reduced by 10 mmol/L MitoT cotreatment (nZ 6 to 11). C: DNP-induced
to 11). One ﬂuorescent unit equals 3.2  103 E. coli CFU (2-hour ﬂuxes). Data are g
The American Journal of Pathology - ajp.amjpathol.orgdecrease in TER occurred (Figure 2A). Moreover, bacterial
translocation was substantially increased (Figure 2B), high-
lighting the impact of metabolic stress in the context of
commensal bacteria on gut permeability. The drugs, at the
doses used, did not cause epithelial apoptosis and were neither
bacteriostatic nor bacteriocidal (data not shown); however,
they did lower epithelial ATP levels by approximately 25 to
30% (Figure 2A), consistent with previous ﬁndings.19
Seeking to differentiate between paracellular and trans-
cellular bacterial translocation,10 treatment with gentamicin
revealed a signiﬁcant increase in E. coli internalization into
epithelia treated with the metabolic stressors (Figure 2, C and
D), and a portion of the bacteria escaped death and re-entered
the culture medium (Figure 2E) [ﬁndings reproduced with the
HT-29 epithelial cell line (Figure 2E) and E. coli (F18; data not
shown)]. Macrophages treated with DNP retained their ability
to acidify the phagosome (data not shown), suggesting that
reduced phagosomal killing did not underlie the escape of
E. coli fromDNP-treated epithelia. Althoughmany stimuli can
perturb mitochondrial function,13 indomethacin-induced en-
teropathy has been associated with mitochondrial dysfunction
and, corroborating the ﬁndings herein, we have provided data
implicating reactive oxygen species (ROS) in indomethacin-
induced increased bacterial translocation across T84 epithe-
lial cell monolayers.22
More important, H2O2 added to T84-epithelia (ie, extracel-
lular ROS20) did not signiﬁcantly increase the internalization of
E. coli (Figure 2F), suggesting that the DNP-evoked increased
bacterial internalization could be via intracellular ROS signaling.
Blocking Mitochondrial ROS Reduces Bacteria
Internalization and Transcytosis
Perturbation of mitochondrial function causes ROS ge-
neration.23,33 Although DNP might be predicted to elicit
mitochondrial ROS, the possibility of phagosome- or endo-
plasmic reticulum (ER)-derived ROS, perhaps because ofman colon are inhibited by MitoTEMPO (MitoT). Biopsy specimens from normal
a decrease in TER (A) and increased ﬂux of 51Cr-EDTA (B), with the latter being
increases in FITC-labeled dead E. coli (K12) ﬂux is suppressed by MitoT (nZ 6
iven as means  SEM. *P < 0.05 versus control (con) and DNP.
2521
Wang et alcommunication with mitochondria,34 was addressed by ex-
periments withMitoSOX to ﬂuorescently detect mitochondria-
derived superoxide, and MitoTEMPO and mQ, antioxidants
whose physicochemical properties direct them to mitochon-
dria.35 There was marked up-regulation of mitochondrial su-
peroxide in DNP, with or without E. colietreated epithelia
(Figure 3A), compared with controls or DNP only. Use of
MTAs partially inhibited the decrease in TER (Figure 3B) and,
more important, substantially reduced bacterial internalization,
release (Figure 2E), and translocation (Figure 3, C and D)
across T84-epithelia.Figure 5 Tissues from patients with Crohn’s disease display increased
baseline E. coli ﬂux that is signiﬁcantly enhanced by metabolic stress and
reduced by MitoTEMPO. A: qPCR on biopsy specimens from patients withMTAs Block Epithelial Barrier Dysfunction in Crohn’s
Disease
Analysis of control human colonic tissue (Table 1) in Ussing
chambers revealed DNP-evoked decreases in TER, and
increased transepithelial ﬂuxes of 51Cr-EDTA (paracellular
marker) and E. coli (Figure 4). MitoTEMPO cotreatment did
not affect the decrease in TER but signiﬁcantly reduced the
ﬂuxes of 51Cr-EDTA and E. coli.
Quantitative PCR (qPCR) revealed up-regulation of
peroxiredoxin-1 (a cytosolic antioxidant) and ATP-synthase
mRNA in inﬂamed biopsy specimens from patients with
Crohn’s disease, consistent with a compensatory response to
oxidative stress (Figure 5A), adding additional support for
assessing the impact of metabolic stress in this disorder
(NADHCoQ reductase mRNAwas unaffected). Also, 50% of
biopsy specimens from patients with inactive disease displayed
increased peroxiredoxin-1 and ATP-synthase mRNA, begging
the questions if this is indicative of low-grade inﬂammation
and/or a propensity for relapse and if markers of mitochondrial
function could be predictive for relapses in IBD.
Tissue from patients with Crohn’s disease displayed a
signiﬁcant increase in baseline E. coli ﬂux, consistent with a
barrier defect,8,9 that was increased approximately sevenfold
by DNP, indicating enhanced susceptibility to oxidative
stress (Figure 5).9 Remarkably, MitoTEMPO reduced the
DNP-induced transepithelial ﬂux of E. coli in all six patients
by 7% to 71% (Figure 5). However, the increased baseline
translocation of E. coli was unaffected by MitoTEMPO
cotreatment (n Z 4).Crohn’s disease (each bar indicates a patient) reveals increased expression
of peroxiredoxin-1 and ATP synthase mRNA, indicative of a response to
metabolic stress. B: E. coli ﬂux across biopsy specimens from patients
with Crohn’s disease mounted in Ussing chambers is signiﬁcantly
increased by 0.1 mmol/L DNP, and this barrier defect is inhibited by 10
mmol/L MitoTEMPO (MitoT). One ﬂuorescent unit equals 3.2  103 E. coli
CFU (2-hour ﬂuxes). *P < 0.05, **P < 0.01 versus the indicated group.
Con, control.Systemic Delivery of MitoTEMPO Reduces Murine Colitis
Four different protocols were used to assess the impact of
systemic delivery of MitoTEMPO on murine colitis
(Figure 1). Analysis of mice after 3 days of exposure to
DSS revealed, as expected, only minor macroscopic dis-
ease (compare Figures 6A and 7A), no loss of body weight,
and mild derangement of colonic architecture (Figure 6, A
and B). However, there was a signiﬁcant increase in the
lumen-to-blood ﬂux of FITC-dextran (4 kDa) (Figure 6C)
and a subtle reduction in epithelial mitochondrial VDAC
protein expression (Figure 6D). These early epithelial2522defects could be important in the manifestation of DSS-
induced colitis.
Severe colitis was obvious in mice exposed to DSS for 5
days (Figure 7, AeD) (3 days normal water) (Figure 7B).
Mice receiving MitoTEMPO as a prophylactic (Figure 7, A
and B) or a treatment (Figure 7C) developed signiﬁcantlyajp.amjpathol.org - The American Journal of Pathology
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The American Journal of Pathology - ajp.amjpathol.orgless severe disease. Epithelial barrier function, as assessed
by FITC-dextran ﬂuxes and culture of bacteria from gut
segments, was substantially reduced in MitoTEMPO-treated
mice (Figure 7A). Segments of colon from DSS-treated
mice mounted in Ussing chambers revealed characteristic
reductions in forskolin-stimulated short-circuit current,36
indicative of altered epithelial electrogenic ion transport,
which were unaffected by MitoTEMPO (data not shown).
MitoTEMPO Reduces DSS-Induced ProInﬂammatory
Cytokine Protection in Vitro
In contrast to lipopolysaccharide, DSS-evoked increases in
IL-8 production by T84 epithelia were inhibited by Mito-
TEMPO (Figure 8).
Discussion
Maintenance of the epithelial barrier or restoration of a
defective barrier is an important component of intestinal ho-
meostasis, and a laudable goal in treating intestinal inﬂam-
matory diseases, such as IBD. Yet, despite the fact that the
control of paracellular and transcellular permeation is critically
energy dependent, the potential to target the epithelial mito-
chondria to extrinsically regulate gut function has not been
addressed. This is surprising given that many of the stimuli that
derange mitochondrial activity (eg, toxins and psychological
stress10) are implicated in IBD pathogenesis or as triggers of
disease relapse, and in the light of the putative roles of auto-
phagy37 and ER stress38 in IBD, both of which impinge on
mitochondrial biology.20 Indeed, in many respects, mito-
chondria and the ER can be considered a functional unit.34
Herein, we extend our previous ﬁndings13,21 showing that
perturbed mitochondrial activity increases epithelial perme-
ability by demonstrating, for the ﬁrst time to our knowledge,
that mitochondria-derived superoxide is crucial for the
increased transcellular permeation of commensal bacteria and
that this can be countered by MTAs. In addition, perturbed
epithelial mitochondria and increased gut permeability are
identiﬁed as early events in DSS-induced colitis and Mito-
TEMPO reduced the severity of DSS-induced colitis, corre-
lating with improved barrier function and an ability to suppress
proinﬂammatory cytokine output. These mechanistic studiesFigure 6 Increased intestinal permeability is an early feature of DSS-
induced colitis. BALB/c mice were exposed to 5% DSS for 3 days, with or
without 100 mg MitoTEMPO (MitoT; i.p., daily), and colitis was assessed
(Figure 1). A and B: DSS-treated mice appear normal, but on autopsy show
signs of mild macroscopic disease (n Z 11 to 12, three experiments) and
histological damage (nZ 3 to 4) (compare to Figure 7) that is reduced in Mito
þ DSS-treated mice. C: Lumen-to-blood ﬂux of FITC-dextran (4 kDa) increases
in the DSS-treated mice and is inhibited by MitoT (n Z 7 to 8, two experi-
ments). D: Immunoblotting of whole cell extracts of isolated colonic epithelial
cells reveals a modest reduction in the mitochondria-speciﬁc VDAC protein.
Data are given as means  SEM. *P < 0.05 versus control (cont), yP < 0.05
versus DSS. Original magniﬁcation,200 (H&E images). L, lumen of colon; m,
external muscle layers.
2523
Figure 7 A: MitoTEMPO (MitoT) suppresses
colitis (nZ 14) that is accompanied by enhanced
barrier function measured by FITC-dextran ﬂux
(n Z 3) and translocation of bacteria into the
mucosa (n Z 5 to 10). BeD: The anticolitic
beneﬁt of MitoTEMPO in the prolonged DSS model
(Figure 1); MitoTEMPO used as either a prophy-
lactic or a treatment signiﬁcantly reduces macro-
scopic and histological disease. Data are given as
means  SEM [n Z 15 to 19 mice from four ex-
periments and ﬁve mice from one experiment in
the prophylactic (III) and treatment (IV) regi-
mens, respectively]. *P < 0.05 versus control
(con), yP < 0.05 versus DSS. Original magniﬁca-
tion, 200 (H&E images). L, lumen of colon; m,
external muscle layers.
Wang et alhighlight the importance of mitochondria, speciﬁcally
mitochondria-derived superoxide, as a signaling molecule, in
the control of epithelial barrier function and host-bacteria in-
teractions in the gut.
Although increases in paracellular permeability are readily
demonstrable in models of colitis and IBD,3 a contribution
from increased transcellular permeation to a barrier defect is
poorly understood. Certainly, mitochondrial dysfunction in-
creases paracellular permeability, but herein we opted to focus
on transcellular permeability because of the paucity of data in
this area. Juxtaposing our analyses of metabolic stress13 with
assessment of bacterial pathogens39 and proinﬂammatory cy-
tokines40 on model human colon-derived epithelial cells, a
body of evidence is emerging that underlines the need to2524incorporate consideration of transcellular passage of microbes/
antigens into any discussion of epithelial barrier function.
Additional emphasis is given to this perspective because
internalization of bacteria would be expected to activate the
enterocyte, with putative consequences for mucosal immunity.
Themechanism bywhich perturbed epithelialmitochondrial
activity (DNP, rotenone, and oligomycin A evoked) resulted
in internalization and translocation of two noninvasive
commensal E. coli strains remained an open question. Earlier
pharmacological and molecular analyses had indicated a role
for NF-kB in theDNP-induced epithelial barrier dysfunction,21
and we hypothesized that ROS participated in this event,
noting that some inhibitors of NF-kB (eg, pyrrolidine dithio-
carbamate) can have antioxidant activity.ajp.amjpathol.org - The American Journal of Pathology
Figure 8 IL-8 production by T84 epithelia exposed to DSS is suppressed
by cotreatment with 10 mmol/L Provided reagents MitoTEMPO (MitoT). Data
are given as means  SEM (n Z 9 cell preparations from three separate
experiments). *P < 0.05 versus control, yP < 0.05 versus DSS.
Mitochondria and Epithelial PermeabilityThe ROS are a natural by-product of the electron transport
chain,35 and although a plethora of antioxidants exist to restrict
ROS-driven cytotoxicity, a burgeoning literature attests to the
signaling roles that ROS play.33,34 Increased T84 cell ROS
production accompanied DNP and/or E. coli exposure, and the
latter is in accordance with data from Neish and colleagues41
showing that commensal bacteria can elicit epithelial ROS
production. This could be of particular relevance in gut disease,
where mucus depletion allows direct bacteria-epithelial con-
tact.42 However, only when combined with metabolic stress
(eg, DNP) was signiﬁcant internalization and passage of
noninvasive, commensal E. coli across epithelial monolayers
observed in our study; these are ﬁndings we have also reca-
pitulated in normal human colon mounted in Ussing chambers.
Given the prominent role of the commensal microbiota in
enteric inﬂammatory disease43 and the relapsing-remitting na-
ture of IBD, we speculate that perturbed host-bacteria interac-
tion as a consequence of deranged mitochondrial activity and
the concomitant increase in epithelial permeability, notably
internalization and transcellular passage of microbes, contribute
to the reactivation of enteric inﬂammation. Additional credence
is given to this supposition by the increased sensitivity to
uncoupling of oxidative phosphorylation in IBD, as demon-
strated by the enhanced bacterial transcytosis across DNP-
treated biopsy specimens from patients with Crohn’s disease.
Mitochondria are the major, but not the only, cellular source
of ROS and so mechanistically it was important to assess the
source of the ROS. Immunolocalization with Mitosox and use
of MTAs indicated that mitochondrial superoxide predomi-
nantly drives the internalization and transcytosis of E. coli
across stressed epithelium, in both cell lines in culture and
human colonic tissue assessed ex vivo. Moreover, extracellular
H2O2 (to mimic an inﬂammatory state) did not increase
epithelial internalization of E. coli, suggesting that the
ROS effect observed may be due to speciﬁc targeting of
intracellular-generated ROS that cannot be recapitulated by
extracellular ROS despite its ability to cross the cell membrane.
Previous studies revealed no obvious apoptosis in DNP-treatedThe American Journal of Pathology - ajp.amjpathol.orgepithelia within the parameters of the experiment.19,21,44
Collectively, these data are compatible with a scenario in
which superoxide generated through perturbed mitochondrial
function, along with a concomitant reduction in ATP,19 triggers
the uptake of extracellularmaterial for catabolism.We posit that
this is a conserved cell survival mechanism45; having sensed
metabolic stress, the cell seeks to internalize material for
catabolism. The paradox therein is that, in the gut, excessive
endocytosis of commensal bacteria could activate the enter-
ocyte, provoking local inﬂammation that would be exaggerated
further by the enhanced transcytosis of bacteria. Extrapolating
from this, the hypothesis arises that MTAs, by virtue of their
barrier-enhancing effect, could be used to treat colitis or prolong
periods of disease remission. Protective effects of MTAs (ie,
mQ and MitoE) have been shown in models of sepsis,46,47 but
gut permeability was not assessed in those studies.
Increased gut permeability as a forerunner to colitis has been
demonstrated in IL-10/ and MDR1/ mice,6,7 and pene-
tration of bacteria deep into the mucus layer may occur in mice
exposed to DSS before the development of inﬂammation.48
Herein, increased epithelial permeability and perturbed mito-
chondrial function (ie, mild reduction in VDAC expression)
were noted early in the course of DSS: both irregularities were
prevented by MitoTEMPO treatment. The prevention of the
barrier defect deﬁned by 4-KDa FITC-dextran is noteworthy,
raising issues relating to the site of the barrier defect (eg, small
versus large intestine), nature of the defect (ie, tight junction
disruption or transcellular, altered epithelial apoptosis or pro-
liferation), and target cell for the MitoTEMPO (ie, direct or
indirect effects), all of which require a more extensive inquiry.
Subsequently, it was determined that mice receiving Mito-
TEMPO had signiﬁcantly less DSS-induced disease in all of
the paradigms tested (Figure 1). Moreover, and in accordance
with the in vitro analyses of human colon, the anticolitic effect
of MitoTEMPO was associated with enhanced barrier func-
tion, asmeasured by transepithelial FITC-dextran and bacterial
ﬂuxes. Collectively, these data underline the link between
mitochondria, epithelial permeability, and the development of
inﬂammation.
Macrophage and epithelial activation (or death) have been
implicated in DSS-induced colitis.49 In this context, Mito-
TEMPO suppression of DSS-induced tumor necrosis factor-
a (a pivotal cytokine in IBD41; personal observation) and
IL-8 (a potent neutrophil chemokine) synthesis by macro-
phages and epithelia, respectively, would be an important
facet, in conjunction with enhanced epithelial barrier func-
tion, of MTA suppression of colitis. Indeed, these data
complement the recent demonstration of suppression of
inﬂammasome activation and IL-1b and IL-18 synthesis in
the human THP-1 macrophage cell line by the MTA, mQ.50
In summary, metabolic stress compromises epithelial bar-
rier function, promoting the transcytosis of bacteria across the
epithelial layer that occurs, at least partially, via transcellular
permeation. This oxidative stresseinduced barrier defect may
be particularly relevant because i) the commensal bacteria
have been implicated in the etiology of IBD, ii) it would allow2525
Wang et alactivation of the enterocyte, and iii) colonic tissue from pa-
tients with Crohn’s disease was sensitive to the uncoupling of
oxidative phosphorylation, much more so than tissue from
controls. These barrier defects in human tissues, and those
observed in DSS-treated mice, and the severity of DSS-colitis
were all ameliorated byMTA.We present these novel ﬁndings
as proof-of-principle data to support the consideration of
MTAs in IBD, a process that could be expedited as MTAs are
undergoing assessment in a clinical trial.46
Acknowledgments
We thank the IBD Intestinal Tissue Bank at the University
of Calgary for assistance with patient samples and ethics
approval.
Author contributions were as follows: study design, J.D.S.
and D.M.M.; generation of data, A.W., A.V.K., V.P.,
C.M.M., I.S., J.L., M.F., N.R., D.B., andM.D.; data analysis,
A.W., A.V.K., V.P., C.M.M., I.S., J.L., M.F., P.L.B., J.D.S.,
and D.M.M.; provided reagents, M.P.M.; writing of manu-
script, W.K.M., J.D.S., and D.M.M.; and review of manu-
script, A.W., A.V.K., V.P., C.M.M., I.S., J.L., M.P.M., M.F.,
N.R., D.B., R.Y., M.D., P.L.B., W.K.M., J.D.S., and D.M.M.
References
1. Hooper LV, Gordon JI: Commensal host-bacterial relationships in the
gut. Science 2001, 292:1115e1118
2. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R:
Diversity, stability and resilience of the human gut microbiota. Nature
2012, 489:220e230
3. Turner JR: Intestinal mucosal barrier function in health and disease.
Nat Rev Immunol 2009, 9:799e809
4. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY,
et al: Host-microbe interactions have shaped the genetic architecture
of inﬂammatory bowel disease. Nature 2012, 491:119e124
5. Hollander D: Crohn’s disease: a permeability disorder of the tight
junction? Gut 1988, 29:1621e1624
6. Madsen KL, Malfair D, Gray D, Doyle JS, Jewell LD, Fedorak RN:
Interleukin-10 gene-deﬁcient mice develop a primary intestinal
permeability defect in response to enteric microﬂora. Inﬂamm Bowel
Dis 1999, 5:262e270
7. Resta-Lenert S, Smitham J, Barrett KE: Epithelial dysfunction associ-
ated with the development of colitis in conventionally housed mdr1a-/-
mice. Am J Physiol Gastrointest Liver Physiol 2005, 289:G153eG162
8. Zeissig S, Bürgel N, Günzel D, Richter J, Mankertz J,
Wahnschaffe U, Kroesen AJ, Fromm M, Schlzke JD: Changes in
expression and distribution of claudins 2, 5 and 8 lead to discontin-
uous tight junctions and barrier dysfunction in active Crohn’s disease.
Gut 2007, 56:61e72
9. Söderholm JD, Peterson KH, Olaison G, Frazén LE, Weström B,
Magnusson KE, Sjödahl R: Epithelial permeability to proteins in the
non-inﬂamed ileum of Crohn’s disease. Gastroenterology 1999, 117:
65e72
10. Schoultz I, Söderholm JD, McKay DM: Is metabolic stress a common
denominator in inﬂammatory bowel disease? Inﬂamm Bowel Dis
2011, 17:2008e2018
11. Rodiger WE: The colonic epithelium in ulcerative colitis: an energy-
deﬁciency disease? Lancet 1980, 2:712e715
12. Singh S, Graff LA, Bernstein CN: Do NSAIDs, antibiotics, infections
or stress trigger ﬂares in IBD? Am J Gastroenterol 2009, 4:1298e1313252613. Nazli A, Yang PC, Jury J, Howe K, Watson JL, Söderholm JD,
Sherman PM, Perdue MH, McKay DM: Epithelia under metabolic
stress perceive commensal bacteria as a threat. Am J Pathol 2004,
164:947e957
14. Rodenburg W, Keijer J, Kramer E, Vink C, van der Meer R, Bovee-
Oudenhoven IM: Impaired barrier function by dietary fructo-
oligosaccharides in rats is accompanied by increased colonic
mitochondrial gene expression. BMC Genomics 2008, 9:1441e1451
15. Ma C, Wickham ME, Guttman JA, Deng W, Walker J, Madsen KL,
Jacobson K, Vogl WA, Finlay BB, Vallance BA: Citrobacter
rodentium infection causes both mitochondrial dysfunction and
epithelial barrier disruption in vivo: role of mitochondrial associated
protein (Map). Cellul Microbiol 2006, 6:1669e1686
16. Chowdhury SK, Smith DR, Fernyhough R: The role of aberrant
mitochondrial bioenergetics in diabetic neuropathy. Neurobiol Dis
2013, 51:56e65
17. Rath E, Haller D: Inﬂammation and cellular stress: a mechanistic link
between immune-mediated and metabolically-driven pathologies. Eur
J Nutr 2011, 50:219e233
18. Tarnapolsky MA, Raha S: Mitochondrial myopathies: diagnosis,
exercise intolerance, and treatment options. Med Sci Sports Exerc
2005, 37:2086e2093
19. Nazli A, Wang A, Steen O, Prescott D, Lu J, Perdue MH,
Söderholm JD, Sherman PM, McKay DM: Enterocyte cytoskeletal
changes are crucial for enhanced translocation of nonpathogenic
Escherichia coli across metabolically stressed gut epithelium. Infect
Immun 2006, 74:192e201
20. Tschopp J: Mitochondria: sovereign of inﬂammation? Eur J Immunol
2011, 41:1196e1202
21. Lewis K, Caldwell J, Phan V, Prescott D, Nazli A, Wang A,
Söderholm JD, Perdue MH, Sherman PM, McKay DM: Decreased
epithelial barrier function evoked by exposure to metabolic stress and
nonpathogenic E. coli is enhanced by TNFa. Am J Physiol Gastro-
intest Liver Physiol 2008, 294:G669eG678
22. Schoultz I, McKay CM, Graepel R, Phan VC, Wang A,
Söderholm JD, McKay DM: Indomethacin-induced translocation of
bacteria across enteric epithelia is reactive oxygen species-dependent
and reduced by vitamin C. Am J Physiol Gastrointest Liver Physiol
2012, 303:G536eG545
23. Rodriguez-Cuenca S, Cochemé HM, Logan A, Abakumova I,
Prime TA, Rose C, Vidal-Puig A, Smith AC, Rubinsztein DC,
Fearnley IM, Jones BA, Pope S, Heales SJ, Lam BY, Neogi SG,
McFarlane I, James AM, Smith RA, Murphy MP: Consequences of
long-term oral administration of the mitochondria-targeted antioxi-
dant MitoQ to wild-type mice. Free Radic Biol Med 2010, 48:
161e172
24. Keita ÅV, Salim SY, Jiang T, Yang PC, Franzén L, Söderkvist P,
Magnusson KE, Söderholm JD: Increased uptake of non-pathogenic
E. coli via the follicle-associated epithelium in longstanding ileal
Crohn’s disease. J Pathol 2008, 215:135e144
25. Zhou R, Yazdi AS, Menu P, Tschopp J: A role for mitochondria in
NLRP3 inﬂammasome activation. Nature 2011, 469:221e225
26. Yates RM, Russel DG: Real-time spectroﬂuorometric for the lumen
environment of the maturing phagosome. Methods Mol Biol 2008,
445:311e325
27. Rybicka JM, Balce DR, Chaudhuri S, Allan ER, Yates RM:
Phagosomal proteolysis in dendritic cells is modulated by
NADPH oxidase in a pH-independent manner. EMBO J 2012, 31:
932e944
28. Lu J, Wang A, Ansari S, Hersberg RM, McKay DM: Intra-colonic
delivery of bacterial superantigens evokes an inﬂammatory response
and exaggerates disease in mice recovering from colitis. Gastroen-
terology 2003, 125:1785e1795
29. Asfaha S, Bell CJ, Wallace JL, MacNaughton WK: Prolonged
colonic epithelial hyporesponsiveness after colitis: role of inducible
nitric oxide synthase. Am J Physiol Gastrointest Liver Physiol 1999,
276:G703eG710ajp.amjpathol.org - The American Journal of Pathology
Mitochondria and Epithelial Permeability30. Prescott D, McKay DM: Aspirin-triggered lipoxin enhances macro-
phage phagocytosis of bacteria while inhibiting inﬂammatory cyto-
kine production. Am J Physiol Gastrointest Liver Physiol 2011, 301:
G487eG497
31. Diaz-Granados N, Howe K, Lu J, McKay DM: Dextran sulphate
sodium-induced colonic histopathology, but not altered epithelial ion
transport, is reduced by inhibition of phosphodiesterase activity. Am J
Pathol 2000, 156:2169e2177
32. Smyth D, McKay CM, Gulbransen BD, Phan V, Wang A,
McKay DM: Interferon-ª signals via an ERK1/2-ARF6 pathway to
promote bacterial internalization by gut epithelia. Cellul Microbiol
2012, 14:1257e1270
33. Marchi S, Giorgi C, Suski JM, Agnoletto C, Bononi A, Bonora M, De
Marchi E, Missiroli S: Mitochondria-ROS crosstalk in the control of
cell death and aging. J Signal Transduct 2012, 2012:329635
34. Bravo R, Vicencio JM, Parra V, Troncoso R, Munoz JP, Bui M,
Quiroga C, Rodriguez AE, Verdejo HE, Ferreira J, Iglewski M,
Chiong M, Simmen T, Zorzano A, Hill JA, Rothermel BA,
Szabadkai G, Lavandero S: Increased ER-mitochondrial coupling
promotes mitochondrial respiration and bioenergetics during early
phases of ER stress. J Cell Sci 2011, 124:2143e2152
35. Reily C, Mitchell T, Chacko BK, Benavides G, Murphy MP, Darley-
Usmar V: Mitochondrially-targeted compounds and their impact on
cellular bioenergetics. Redox Biol 2013, 1:86e93
36. Hirota CL, McKay DM: Loss of Ca2þ-mediated ion transport during
colitis correlates with reduced ion transport responses to a Ca-
activated K channel opener. Br J Pharmacol 2009, 156:1085e1097
37. Travassos LH, Carneiro LA, Ramjeet M, Hussey S, Kim YG,
Magalhães JG, Yuan L, Soares F, Chea E, Le Bourhis L, Boneca IG,
Allaoui A, Jones NL, Nuñez G, Girardin SE, Philpott DJ: Nod1 and
Nod2 direct autophagy by recruiting ATG16L1 to the plasma mem-
brane at the site of bacterial entry. Nat Immunol 2010, 11:55e62
38. Kaser A, Lee AH, Franke A, Glickman JN, Zeissig S, Tilg H,
Nieuwenhuis EE, Higgins DE, Schreiber S, Glimcher LH, Blumberg RS:
XBP1 links ER stress to intestinal inﬂammation and confers genetic risk
for human inﬂammatory bowel disease. Cell 2008, 134:743e756
39. Kalischuk LD, Inglis GD, Buret AG: Campylobacter jejuni infection
induces transcellular translocation of commensal bacteria via lipid
rafts. Gut Pathog 2009, 1:2e
40. Clark E, Hoare C, Tanianis-Hughes J, Carlson GL, Warhurst G:
Interferon-ª induces translocation of commensal Escherichia coli
across gut epithelial cells via a lipid raft-mediated process. Gastro-
enterology 2005, 128:1258e1267The American Journal of Pathology - ajp.amjpathol.org41. Swanson PA II, Kumar A, Samarin S, Vijay-Kumar M, Kundu K,
Murthy N, Hansen J, Nusrat A, Neish AS: Enteric commensal bac-
teria potentiate epithelial restitution via reactive oxygen species-
mediated inactivation of focal adhesion kinase phosphatases. Proc
Natl Acad Sci U S A 2011, 108:8803e8808
42. Vaishnava S, Yamamoto M, Severson KM, Ruhn KA, Yu X,
Koren O, Ley R, Wakeland EK, Hooper LV: The antibacterial lectin
RegIIIª promotes the spatial segregation of microbiota and host in
the intestine. Science 2011, 334:255e258
43. Knights D, Lassen KG, Xavier RJ: Advances in inﬂammatory bowel
disease pathogenesis: linking host genetics and the microbiome. Gut
2013, 62:1505e1510
44. Lewis K, Lutgendorff F, Phan V, Söderholm JD, Sherman PM,
McKay DM: Enhanced translocation of bacteria across metabolically-
stressed epithelia is reduced by butyrate. Inﬂamm Bowel Dis 2010,
16:1138e1148
45. Ryder TA, Bowen ID: Endocytosis and aspects of autophagy in the
foot epithelium of the slug Agriolimax reticulatus (Muller). Cell
Tissue Res 1977, 181:129e142
46. Zang QS, Sadek H, Maass DL, Martinez B, Ma L, Kilgore JA,
Williams NS, Frantz DE, Wigginton JG, Nwariaku FE, Wolf SE,
Minei JP: Speciﬁc inhibition of mitochondrial oxidative stress sup-
presses inﬂammation and improves cardiac function in a rat
pneumonia-related sepsis model. Am J Physiol Heart Circ Physiol
2012, 302:H1847eH1859
47. Lowes DA, Webster NR, Murphy MP, Galley HF: Antioxidants that
protect mitochondria reduce interleukin-6 and oxidative stress,
improve mitochondrial function, and reduce biochemical markers of
organ dysfunction in a rat model of acute sepsis. Br J Anaesth 2013,
110:472e480
48. Johansson ME, Gustafsson JK, Sjöberg KE, Petersson J, Holm L,
Sjövall H, Hansson GC: Bacteria penetrate the inner mucus layer
before inﬂammation in the dextran sulphate colitis model. PLoS One
2010, 5:e12238
49. Mahler M, Bristol IJ, Leiter EH, Workman AE, Birkenmeier EH,
Elson CO, Sundberg JP: Differential susceptibility of inbred mouse
strains to dextran sulfate sodium-induced colitis. Am J Physiol Gas-
trointest Liver Physiol 1988, 274:G544eG551
50. Dashdoji A, Jyothi KR, Lim S, Jo A, Nguyen MN, Ha J, Yoon KS,
Kim HJ, Park JH, Murphy MP, Kim SS: Mitochondria-targeted
antioxidant MitoQ ameliorates experimental mouse colitis by sup-
pressing inﬂammasome-mediated inﬂammatory cytokines. BMC Med
2013, 11:1782527
